$54.14
0.00% today
Nasdaq, Feb 28, 04:47 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock price

$54.14
+0.80 1.50% 1M
-2.18 3.87% 6M
+5.91 12.25% YTD
+5.93 12.30% 1Y
+1.69 3.22% 3Y
+5.98 12.42% 5Y
+5.28 10.81% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.81 1.47%
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Key metrics

Market capitalization $135.74b
Enterprise Value $146.82b
P/E (TTM) P/E ratio 22.53
EV/FCF (TTM) EV/FCF 18.46
EV/Sales (TTM) EV/Sales 3.30
P/S ratio (TTM) P/S ratio 3.05
P/B ratio (TTM) P/B ratio 1.69
Dividend yield 3.76%
Last dividend (FY24) $2.04
Revenue growth (TTM) Revenue growth -4.57%
Revenue (TTM) Revenue $44.44b
EBIT (operating result TTM) EBIT $10.28b
Free Cash Flow (TTM) Free Cash Flow $7.95b
EPS (TTM) EPS $2.40
P/E forward 15.37
P/S forward 2.77
EV/Sales forward 2.99
Short interest 0.22%
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Sanofi Sponsored ADR forecast:

19x Buy
79%
4x Hold
17%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
79%
Hold
17%
Sell
4%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
44,435 44,435
5% 5%
100%
- Direct Costs 16,222 16,222
9% 9%
37%
28,213 28,213
2% 2%
63%
- Selling and Administrative Expenses 6,005 6,005
5% 5%
14%
- Research and Development Expense 7,998 7,998
10% 10%
18%
14,210 14,210
6% 6%
32%
- Depreciation and Amortization 3,927 3,927
25% 25%
9%
EBIT (Operating Income) EBIT 10,283 10,283
4% 4%
23%
Net Profit 6,015 6,015
3% 3%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Positive
Reuters
2 days ago
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, researchers reported.
Neutral
GlobeNewsWire
3 days ago
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma  Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple m...
Neutral
GlobeNewsWire
6 days ago
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvement Findings to f...
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 84,587
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today